|
| Polyphenols | Status | Conditions | Purpose | Intervention | Phase | http://ClinicalTrials.gov identifier |
|
| NAFLD | Curcumin | Not yet recruiting | NAFLD patients with type 2 diabetes | Evaluate the effects of curcumin supplement on metabolic factors and hepatic fibrosis | 1500 mg, 1 capsule/day for 12 weeks | 2/3 | NCT02908152 |
| Caffeine and chlorogenic acid | Not yet recruiting | NAFLD patients with type 2 diabetes | Investigate the effects of caffeine and chlorogenic acid supplements on inflammatory, metabolic factors, hepatic steatosis, and fibrosis | 200 mg/d for 6 months | 2/3 | NCT02929901 |
| Resveratrol | Completed | Obese men with NAFLD | Evaluate potential metabolic effects of resveratrol | 500 mg 3 times daily for six months | 1 | NCT01446276 |
| Resveratrol | Completed | Overweight adolescents with NAFLD and type 2 diabetes or metabolic syndrome | Demonstrate the safety and tolerability of resveratrol therapy | 75 mg twice daily for a total daily dose of 150 mg for the duration of 30 days | 2/3 | NCT02216552 |
| Resveratrol | Completed | Obese patients with NAFLD/NASH | Evaluate the effects of resveratrol | 500 mg 3 times daily for 6 months | 1 | NCT01464801 |
| Resveratrol | Completed | Patients with NAFLD/NASH | Evaluate effects of resveratrol supplement on biochemical factors and hepatic fibrosis | One resveratrol capsule per day for 12 weeks | 2/3 | NCT02030977 |
|
| HCV | EGCG, silymarin | Completed | HCV patients | Determine the safety, metabolism, and antioxidant activity | Silymarin capsules, 700 mg, twice daily, 12 days; EGCG capsules, 196.5 mg, twice daily, 12 days | 1 | NCT01018615 |
| Quercetin | Completed | HCV patients | Evaluate safety and antiviral activity | 2000 mg for 28 days | 1 | NCT01438320 |
| Naringenin | Completed | Persons infected with hepatitis C | To evaluate whether it can lower the amount of virus in the blood stream | 1 gram of naringenin mixed with 16 grams of hydroxypropyl-β-cyclodextrin in 250 mL of water | 1 | NCT01091077 |
|
| Cirrhosis and liver cancer | Green tea catechin extract | Not yet recruiting | Cirrhosis | Define how well it is in preventing liver cancer in patients with cirrhosis | Defined green tea catechin extract for 24 weeks | 1 | NCT03278925 |
| Resveratrol | Withdrawn | Liver cancer | Evaluate beneficial effect in the cellular function of normal liver cells and liver cancer cells | 1 g daily for 10 days | 1/2 | NCT02261844 |
|
